[Ip-health] Biotech Industry Organization IGWG delegation

[Sarah Rimmington]

The Biotechnology Industry Organization (BIO) was invited by WHO to be
an expert entity at IGWG II bis. This means they are present in the
negotiating sessions along with member states and other invited entities
and experts.

Their delegation includes three BIO representatives:
=95 Lila Feisee, Managing Director of IP, BIO
=95 Jon Santamauro, Sidley Austin LLP, Consultant to BIO. I note that he wa=
s formerly a U.S. Trade Representative IP attach=E9 in Geneva.
=95 Ms. K. Lai, Director of International Health policy, BIO

BIO have also included the following non-BIO folks in their delegation:

=95 Karen Marie Hauda, Senior Director, Global Government Affairs, Abbott L=
aboratories
=95 Ms. J. Tom of AUTM (The Association of University Technology Managers).=
 Some of you will remember that AUTM is the U.S. body that
backtracked last week on promoting the Institute for Policy Innovation lett=
er regarding IGWG amongst their members due to the hard work of
civil society. They then affirmed their commitment to access in the develop=
ing world for medicines discovered at universities.
=95 Juliano Froehner, R&D consultant. Many of us are familiar with Mr. Froe=
hner as the person who operates the Essential Innovation website.

--
Sarah Rimmington
Attorney
Essential Action, Access to Medicines Project
Washington, DC
Tel: (202) 387-8030
Cell: (202) 422-2687
www.essentialaction.org/access/